This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc., a leading biopharmaceutical company based in the United States, is dedicated to advancing treatments for neuroscience-related disorders. Founded in 2018, the company has quickly established itself in the industry, focusing on innovative therapies for conditions such as schizophrenia, epilepsy, and Parkinson's disease. With a strong emphasis on research and development, Cerevel Therapeutics is known for its unique approach to drug discovery, leveraging insights from neuroscience to create targeted therapies. The company has made significant strides in clinical trials, positioning itself as a key player in the neurology sector. Its commitment to addressing unmet medical needs has garnered attention, making Cerevel a notable name in the biopharmaceutical landscape.
DitchCarbon Score
How does Cerevel Therapeutics Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cerevel Therapeutics Holdings, Inc.'s score of 63 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cerevel Therapeutics Holdings, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of AbbVie Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. Cerevel's climate initiatives are influenced by AbbVie Inc., which has established various reduction targets and commitments. However, specific reduction targets for Cerevel itself have not been disclosed. The company does not appear to have its own climate pledge or specific initiatives listed under the Science Based Targets initiative (SBTi) or other climate frameworks. As a subsidiary, Cerevel may align its sustainability efforts with AbbVie’s broader environmental strategies, which include commitments to reduce greenhouse gas emissions across Scope 1, 2, and 3. However, without specific data or targets from Cerevel, it is challenging to provide a detailed overview of their individual climate commitments or performance. In summary, while Cerevel Therapeutics Holdings, Inc. is part of a larger corporate family with potential climate commitments, it currently lacks publicly available emissions data and specific reduction targets.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cerevel Therapeutics Holdings, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
